Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis

• Conditions: CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis; MedDRA version: 14.1Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disorders; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: EUCTR2005-004008-36-IT
• Lead Sponsor: ISTITUTO GIANNINA GASLINI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01-30
• Last Update Posted: 18 April 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients with CINCA/MUCKLE-WELLS:Patients with CINCA/MUCKLE-WELLS with active disease Patients with systemic juvenile idiopathic arthritis: Patients with systemic juvenile idiopathic arthritis with active disease
Are the trial subjects under 18? yes
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Treatment with anti-TNF therapy Infections on-going Immunosupressive treatment in six previous weeks

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified